• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
GYN

Uncomplicated Cystitis: When to Culture, How to Treat and Recommended Prevention Strategies

image_pdfFavoriteLoadingFavorite

CLINICAL ACTIONS:

Acute uncomplicated cystitis is often readily recognized by patients as a routine bladder infection.  Uncomplicated cystitis rarely progresses to pylonephritis and urosepsis even if untreated. The primary goal of treatment is to relieve symptoms. If a patient presents with pain, urgency and frequent urination

  • Determine if a patient may have pyelonephritis as urine cultures are indicated in all cases of upper urinary tract infection (UTI)
    • Culture: Costo-vertebral angle tenderness | Fever | Chills | Flank pain | Nausea/ vomiting | Recurrent/ persistent symptoms despite treatment
  • In the absence of signs and/or symptoms of pyelonephritis, cultures are not required
  • Consider urinalysis in specific circumstances such as
    • Postmenopausal women who may have intermittent dysuria or urge incontinence without infection
    • Women without a previous history of UTI
  • Women with previous history and recognize UTI symptoms can be treated empirically without urinalysis

Antibiotic Therapy

Note: ACOG has replaced Committee opinion 294 (2011) with Committee Opinion 717 (2017) that recommends the cautious use of sulfonamides and nitrofurantoin in the first trimester of pregnancy due to possible risk of birth defects, if no other alternatives are available (see ‘Related ObG Topics’ below)

  • First-line therapy 
    • Trimethoprim-Sulfamethoxazole (TMP-SMX) 160-800 mg PO BID x 3 days
    • If resistance to TMP-SMX is > 15 to 20%
      • Fosfomycin 3 gm PO single dose
      • Trimethoprim 100 mg PO BID x 3 days
      • Nitrofurantoin 100 mg PO BID x 7 days
  • Fluoroquinolones – avoid as first-line if possible
    • Ciprofloxacin 250 mg BID x 3 days
    • Levofloxacin 250 mg BID x 3 days
    • Norfloxacin 400 mg BID x 3 days
    • Gatifloxacin 200 mg once daily x 3 days
  • Microbial prevention of recurrent UTI
    • Patient can take antimicrobial medications above, using a once-daily regimen
    • If cystitis is associated with sexual activity, consider postcoital prophylaxis
      • Take single dose of antimicrobial medication after sexual intercourse
    • Continue for 6-12 months and reassess

Note: FDA (endorsed in ACOG Practice Advisory) recommends the following

FDA has approved label changes that reserve the use of fluoroquinolone antibacterial medicines when treating acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections (UTI) for patients who do not have alternative treatment options.

SYNOPSIS:

UTI is the most common infection encountered in the outpatient setting. By age 32, half of all women will have had at least one UTI. Recurrence rates are over 25%. Fluoroquinolones are effective, but the recommendation is to avoid as a first-line medication to prevent future resistance and maintain these medications as a second-line treatment when needed.

KEY POINTS:

  • Risk factors include
    • Sexual intercourse | Use of spermacides and diaphragm | Previous UTI | New sexual partner | Increasing parity | Diabetes | Obesity | Kidney stones | indwelling catheter
    • With increasing age, consider vaginal atrophy, pelvic organ prolapse and bladder retention
  • No association between
    • Pre/ postcoital voiding | Daily beverage consumption | Frequency of urination | Delayed urination | Wiping patterns | Tampon use | Douching | Hot tub use | Type of underwear
  • Consider formal urologic evaluation for women with
    • Persistent hematuria | Multiple early recurrences of cystitis with the same bacteria
  • Patients with pyelonephritis with severe/worsening illness or persistent fever 48-72 hours after initiation of antibiotics
    • Image to evaluate for stone, abscess or obstruction
  • Treatment of uncomplicated cystitis should take in to consideration antimicrobial resistance patterns
    • Resistance rates higher than 15 to 20% will require a change in antibiotic class
    • Beta-lactams such as cephalosporins and amoxicillin are less effective due to increasing resistance
  • Nonantimicrobial prevention of recurrent UTI
    • Change spermicides or consider other birth control option | Topical estrogen if menopausal (local may be more beneficial than oral)
  • Note: Do not screen or treat asymptomatic bacteriuria in nonpregnant, premenopausal women

Learn More – Primary Sources:

ACOG Practice Bulletin 91: Treatment of Urinary Tract Infections in Nonpregnant Women

ACOG Committee Opinion 717: Sulfonamides, Nitrofurantoin, and Risk of Birth Defects

Screening for Asymptomatic Bacteriuria in Adults

FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects

Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More »

image_pdfFavoriteLoadingFavorite

< Previous
All GYN Posts
Next >

Related ObG Topics:

ACOG and AUGS Guidance: Asymptomatic Microscopic Hematuria in Women
ACOG Guidance on Use of Sulfonamides and Nitrofurantoin for UTIs in the First Trimester
Do Cranberries Decrease Risk of UTIs?
FDA Fluoroquinolone Warning Including Use for UTI Management

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site